{"id":"NCT05543174","sponsor":"Takeda","briefTitle":"A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)","officialTitle":"An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-16","primaryCompletion":"2023-10-25","completion":"2025-07-25","firstPosted":"2022-09-16","resultsPosted":"2024-10-15","lastUpdate":"2025-08-22"},"enrollment":7,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alagille Syndrome (ALGS)"],"interventions":[{"type":"DRUG","name":"TAK-625","otherNames":["Maralixibat chloride"]}],"arms":[{"label":"TAK-625","type":"EXPERIMENTAL"}],"summary":"The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.\n\nThe participants will be treated with TAK-625 for up to the end of study (about 34 months).\n\nParticipants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.","primaryOutcome":{"measure":"Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22","timeFrame":"From Week 18 to Week 22","effectByArm":[{"arm":"TAK-625","deltaMin":17.643,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/183b4344d3af4327"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":7},"commonTop":["Defaecation urgency","COVID-19","Nasopharyngitis","Upper respiratory tract infection","Arthropod bite"]}}